About Us
Products
Responsibility
Investors
Media
Careers
Worldwide
- North America
  - USA
  - Canada
  - Mexico
- South America
  - Brazil
  - Peru
- Asia Pacific
  - India
  - Bangladesh
  - Thailand
  - Malaysia and Singapore
  - Myanmar
  - Sri Lanka
  - Japan
  - China
- Europe
  - Denmark
  - Finland
  - France
  - Germany
  - Hungary
  - Italy
  - Norway
  - Poland
  - Romania
  - Spain
  - Sweden
  - Switzerland
  - The Netherlands
  - The United Kingdom & Ireland
- Middle East
  - UAE
- Africa
  - Morocco
  - Nigeria
  - South Africa
  - Egypt
- Oceania
  - Australia & New Zealand
- CIS
  - Russia
  - Ukraine
Contact Us

Select Page

SPIL Q4FY26 Financial Results

by ananthi | May 22, 2026 | Press Releases | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Recent Posts

SPIL Q4FY26 Financial Results
Press Release Sun Pharma reports Q4 & full year results for FY26
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis

Recent Comments

About Sun Pharma
- Vision & Values
- Milestones & Recognitions
Operations
Investors
Work with us
- Careers
- Current Openings
Quick Links

Facebook
X
Instagram
Linkdin
Instagram

Copyright © Sun Pharmaceutical Industries Ltd. Privacy Policy | Disclaimer

Top

Important Notice

As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details.